Literature DB >> 22185679

Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells.

Mashenka Dimitrova1, Ivaylo Ivanov, Ralitza Todorova, Nadezhda Stefanova, Veselina Moskova-Doumanova, Tanya Topouzova-Hristova, Veselina Saynova, Elena Stephanova.   

Abstract

Dipeptidyl peptidase IV (DPPIV) was studied in three human lung cells - P (fetal lung-derived cells), A549 (lung adenocarcinoma) and SK-MES-1 (squamous cell carcinoma) using a fluorescent cytochemical procedure developed on the basis of the substrate 4-(glycyl-L-prolyl hydrazido)-N-hexyl-1,8-naphthalimide. The observed differences in the enzyme expression were confirmed by measuring the enzyme hydrolysis of glycyl-L-prolyl-para-nitroanilide. The surface and total dipeptidyl peptidase activities of P cells were correspondingly 7-8 and 3-10 times higher than those of SK-MES-1 and A549 cells. The ratio surface per total activity showed that in P (95%) and A549 (93%) cells the enzyme is associated with the plasmalemma while in SK-MES-1 cells (35%) it is bound to intracellular membranes. In order to compare the results from cell cultures with those in human tumor, the enzyme activity was investigated in cryo-sections of three cases of diagnosed squamous lung carcinoma. DPPIV activity was restricted to the connective tissue stroma surrounding the DPPIV-negative tumor foci. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22185679     DOI: 10.1016/j.tice.2011.11.003

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  7 in total

1.  Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer.

Authors:  Hailey A Clancy; Hong Sun; Lisa Passantino; Thomas Kluz; Alexandra Muñoz; Jiri Zavadil; Max Costa
Journal:  Metallomics       Date:  2012-06-19       Impact factor: 4.526

Review 2.  The expression of proline-specific enzymes in the human lung.

Authors:  Gwendolyn Vliegen; Tom K Raju; Dirk Adriaensen; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Ann Transl Med       Date:  2017-03

3.  Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.

Authors:  Jae-Hwi Jang; Lesley Baerts; Yannick Waumans; Ingrid De Meester; Yoshito Yamada; Perparim Limani; Ignacio Gil-Bazo; Walter Weder; Wolfgang Jungraithmayr
Journal:  Clin Exp Metastasis       Date:  2015-08-02       Impact factor: 5.150

4.  Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.

Authors:  H J Choi; J Y Kim; S-C Lim; G Kim; H J Yun; H S Choi
Journal:  Br J Pharmacol       Date:  2015-10-16       Impact factor: 8.739

5.  Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.

Authors:  Kazuhiko Nakagawa; Takashi Kijima; Morihito Okada; Masahiro Morise; Motoyasu Kato; Katsuya Hirano; Nobukazu Fujimoto; Mitsuhiro Takenoyama; Hiroshi Yokouchi; Yuichiro Ohe; Toyoaki Hida; Keisuke Aoe; Takumi Kishimoto; Masato Hirokawa; Hironori Matsuki; Yutaro Kaneko; Taketo Yamada; Chikao Morimoto; Masayuki Takeda
Journal:  JTO Clin Res Rep       Date:  2021-04-29

Review 6.  CD26/DPP-4 in Chronic Myeloid Leukemia.

Authors:  Anna Sicuranza; Donatella Raspadori; Monica Bocchia
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

Review 7.  The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.

Authors:  Tianli Zhang; Xiang Tong; Shijie Zhang; Dongguang Wang; Lian Wang; Qian Wang; Hong Fan
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.